血清miR-501-3p对肺磨玻璃结节良恶性鉴别诊断的预测价值
Journal: Basic Medical Theory Research DOI: 10.32629/bmtr.v8i2.18889
Abstract
目的：探讨血清miR-501-3p在肺磨玻璃结节（GGN）良恶性鉴别中的诊断价值。方法：收集2022.10-2024.09在成都市双流区第一人民医院确诊的GGN患者160例，分为良性组（GGN-BN）和恶性组（GGN-LUAD）各80例；另取健康对照（Normal）80例。qRT-PCR检测血清miR-501-3p水平，并结合TCGA数据库及自建组织样本验证其表达差异。ROC曲线分析miR-501-3p区分GGN良恶性的诊断效能，生存分析评估预后价值。多因素Logistic回归分析miR-501-3p鉴别诊断 GGN 良恶性的影响因素。结果：miR-501-3p在GGN-LUAD血清和组织中显著低于GGN-BN组（P < 0.01），Normal组与GGN-BN组间无显著差异。miR-501-3p区分GGN-LUAD与GGN-BN的曲线下面积（AUC）为0.771（95%CI：0.700–0.843）。miR-501-3p低表达患者总生存期较短（P = 0.332）。在控制年龄、性别、结节位置等影响因素后，miR-501-3p表达水平升高是GGN恶性风险的保护因素（OR = 0.46, P = 0.001）。结论：miR-501-3p低表达与GGN恶性风险升高及不良预后相关，血清miR-501-3p对 GGN良恶性鉴别具有一定的临床预测价值。
Keywords
肺磨玻璃结节；良恶性；miR-501-3p；鉴别诊断
Full Text
PDF - Viewed/Downloaded: 1 TimesReferences
[1] Siegel RL, Giaquinto AN, Jemal A. Cancer statistics[J]. CA Cancer J Clin, 2024, 74(1):12-49.
[2] Blandin Knight S, Crosbie PA, Balata H, et al. Progress and prospects of early detection in lung cancer[J]. Open Biol, 2017, 7:170070.
[3] 高博,马焱鑫.肺磨玻璃结节CT定量特征诊断肺腺癌的研究进展[J].医学影像学杂志,2025,35(9):159-162.
[4] Mazzone PJ, Lam L. Evaluating the patient with a pulmonary nodule: a review[J]. JAMA. 2022, 327(3):264-273.
[5] 胡锡麟,田凯华.表观遗传修饰调控微小RNA表达在肺癌中的研究进展[J].中国肺癌杂志,2020,23(7):582-588.
[6] Lu J, Zhou L, Wu B, et al. MiR-501-3p functions as a tumor suppressor in non-small cell lung cancer by downregulating RAP1A[J]. Exp Cell Res, 2020, 387(1):111752.
[7] Lei J, Chen P, Zhang F, et al. M2 macrophages-derived exosomal microRNA-501-3p promotes the progression of lung cancer via targeting WD repeat domain 82[J]. Cancer Cell Int, 2021, 21(1):91.
[8] Deng Y, Xia L, Zhang J, et al. Multicellular ecotypes shape progression of lung adenocarcinoma from ground-glass opacity toward advanced stages[J]. Cell Rep Med, 2024, 5(4):101489.
[9] Hu X, Gou J, Wang L, et al. Diagnostic accuracy of low-dose dual-input computed tomography perfusion in the differential diagnosis of pulmonary benign and malignant ground-glass nodules[J]. Sci Rep, 2024, 14(1):17098.
[10] 赵静,范小春.肺磨玻璃结节筛查诊治的研究现状[J].中国医药,2024,19(3):464-468.
[11] Wen X, Yu S, Leng P, et al. MiRNA sequencing of platelet and exosome revealed platelet miR-199b-3p as a potential biomarker in lung adenocarcinoma[J]. Front Immunol, 2025, 16:1619448.
[12] Kim YJ, Kang DH, Cho H, et al. Exosomal microRNA Panels for Detecting Early-Stage Non-Small Cell Lung Cancer[J]. Diagnostics (Basel), 2025, 15(21):2735.
[13] Luo C, Yin D, Zhan H, et al. microRNA-501-3p suppresses metastasis and progression of hepatocellular carcinoma through targeting LIN7A[J]. Cell Death Dis, 2018, 9(5):535.
[14] He L, Chen S, Ying Y, et al. MicroRNA-501-3p inhibits the proliferation of kidney cancer cells by targeting WTAP[J]. Cancer Med, 2021, 10(20):7222-7232.
[15] Zhang Z, Shao L, Wang Y, et al. MicroRNA-501-3p restricts prostate cancer growth through regulating cell cycle-related and expression-elevated protein in tumor/cyclin D1 signaling[J]. Biochem Biophys Res Commun, 2019, 509(3):746-752.
[16] Hong Z, Cui B, Bai X, et al. Meta analysis of the diagnostic value of circulating miRNA in benign and malignant pulmonary nodules[J]. World J Surg Oncol, 2023, 21(1):284.
[17] He Y, Yang Y, Kuang P, et al. Seven-microRNA panel for lung adenocarcinoma early diagnosis in patients presenting with ground-glass nodules[J]. Onco Targets Ther, 2017, 10:5915-5926.
[18] Chen H, Kim AW, Hsin M, et al. The 2023 American Association for Thoracic Surgery (AATS) Expert Consensus Document: management of subsolid lung nodules[J]. J Thorac Cardiovasc Surg, 2024, 168(3):631-647.
[19] Bartlett EC, Kemp SV, Rawal B, et al. Defining growth in small pulmonary nodules using volumetry: results from a "coffee-break" CT study and implications for current nodule management guidelines[J]. Eur Radiol, 2022, 32(3):1912-1920.
[20] 杜歆玥,杨慧龄.循环miRNA作为肺癌诊断和预后无创标志物的研究进展[J].中国医药导报,2020,17(14):31-34.
[21] Tao R, Wang D, Pei W, et al. Highly sensitive and specific panels of plasma exosomal microRNAs for identification of malignant pulmonary nodules[J]. Clin Respir J, 2024, 18(11): e70034.
[22] Poh KC, Ren TM, Ling GL, et al. Development of a miRNA-Based Model for Lung Cancer Detection[J]. Cancers (Basel), 2025, 17(6):942.
[2] Blandin Knight S, Crosbie PA, Balata H, et al. Progress and prospects of early detection in lung cancer[J]. Open Biol, 2017, 7:170070.
[3] 高博,马焱鑫.肺磨玻璃结节CT定量特征诊断肺腺癌的研究进展[J].医学影像学杂志,2025,35(9):159-162.
[4] Mazzone PJ, Lam L. Evaluating the patient with a pulmonary nodule: a review[J]. JAMA. 2022, 327(3):264-273.
[5] 胡锡麟,田凯华.表观遗传修饰调控微小RNA表达在肺癌中的研究进展[J].中国肺癌杂志,2020,23(7):582-588.
[6] Lu J, Zhou L, Wu B, et al. MiR-501-3p functions as a tumor suppressor in non-small cell lung cancer by downregulating RAP1A[J]. Exp Cell Res, 2020, 387(1):111752.
[7] Lei J, Chen P, Zhang F, et al. M2 macrophages-derived exosomal microRNA-501-3p promotes the progression of lung cancer via targeting WD repeat domain 82[J]. Cancer Cell Int, 2021, 21(1):91.
[8] Deng Y, Xia L, Zhang J, et al. Multicellular ecotypes shape progression of lung adenocarcinoma from ground-glass opacity toward advanced stages[J]. Cell Rep Med, 2024, 5(4):101489.
[9] Hu X, Gou J, Wang L, et al. Diagnostic accuracy of low-dose dual-input computed tomography perfusion in the differential diagnosis of pulmonary benign and malignant ground-glass nodules[J]. Sci Rep, 2024, 14(1):17098.
[10] 赵静,范小春.肺磨玻璃结节筛查诊治的研究现状[J].中国医药,2024,19(3):464-468.
[11] Wen X, Yu S, Leng P, et al. MiRNA sequencing of platelet and exosome revealed platelet miR-199b-3p as a potential biomarker in lung adenocarcinoma[J]. Front Immunol, 2025, 16:1619448.
[12] Kim YJ, Kang DH, Cho H, et al. Exosomal microRNA Panels for Detecting Early-Stage Non-Small Cell Lung Cancer[J]. Diagnostics (Basel), 2025, 15(21):2735.
[13] Luo C, Yin D, Zhan H, et al. microRNA-501-3p suppresses metastasis and progression of hepatocellular carcinoma through targeting LIN7A[J]. Cell Death Dis, 2018, 9(5):535.
[14] He L, Chen S, Ying Y, et al. MicroRNA-501-3p inhibits the proliferation of kidney cancer cells by targeting WTAP[J]. Cancer Med, 2021, 10(20):7222-7232.
[15] Zhang Z, Shao L, Wang Y, et al. MicroRNA-501-3p restricts prostate cancer growth through regulating cell cycle-related and expression-elevated protein in tumor/cyclin D1 signaling[J]. Biochem Biophys Res Commun, 2019, 509(3):746-752.
[16] Hong Z, Cui B, Bai X, et al. Meta analysis of the diagnostic value of circulating miRNA in benign and malignant pulmonary nodules[J]. World J Surg Oncol, 2023, 21(1):284.
[17] He Y, Yang Y, Kuang P, et al. Seven-microRNA panel for lung adenocarcinoma early diagnosis in patients presenting with ground-glass nodules[J]. Onco Targets Ther, 2017, 10:5915-5926.
[18] Chen H, Kim AW, Hsin M, et al. The 2023 American Association for Thoracic Surgery (AATS) Expert Consensus Document: management of subsolid lung nodules[J]. J Thorac Cardiovasc Surg, 2024, 168(3):631-647.
[19] Bartlett EC, Kemp SV, Rawal B, et al. Defining growth in small pulmonary nodules using volumetry: results from a "coffee-break" CT study and implications for current nodule management guidelines[J]. Eur Radiol, 2022, 32(3):1912-1920.
[20] 杜歆玥,杨慧龄.循环miRNA作为肺癌诊断和预后无创标志物的研究进展[J].中国医药导报,2020,17(14):31-34.
[21] Tao R, Wang D, Pei W, et al. Highly sensitive and specific panels of plasma exosomal microRNAs for identification of malignant pulmonary nodules[J]. Clin Respir J, 2024, 18(11): e70034.
[22] Poh KC, Ren TM, Ling GL, et al. Development of a miRNA-Based Model for Lung Cancer Detection[J]. Cancers (Basel), 2025, 17(6):942.
Copyright © 2026 皇改改, 冯昊, 闫兰芳, 周宇
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License